SI2138512T1 - Humanizirana anti-NGF protitelesa - Google Patents

Humanizirana anti-NGF protitelesa

Info

Publication number
SI2138512T1
SI2138512T1 SI200431828T SI200431828T SI2138512T1 SI 2138512 T1 SI2138512 T1 SI 2138512T1 SI 200431828 T SI200431828 T SI 200431828T SI 200431828 T SI200431828 T SI 200431828T SI 2138512 T1 SI2138512 T1 SI 2138512T1
Authority
SI
Slovenia
Prior art keywords
cdr
amino acid
acid sequence
humanized anti
heavy chain
Prior art date
Application number
SI200431828T
Other languages
English (en)
Slovenian (sl)
Inventor
Antonio Cattaneo
Sonia Covaceuszach
Doriano Lamba
Original Assignee
Abbott Res Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Res Bv filed Critical Abbott Res Bv
Publication of SI2138512T1 publication Critical patent/SI2138512T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
SI200431828T 2003-12-24 2004-12-23 Humanizirana anti-NGF protitelesa SI2138512T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000601A ITRM20030601A1 (it) 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP09008366A EP2138512B8 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies

Publications (1)

Publication Number Publication Date
SI2138512T1 true SI2138512T1 (sl) 2012-04-30

Family

ID=34708536

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200431828T SI2138512T1 (sl) 2003-12-24 2004-12-23 Humanizirana anti-NGF protitelesa
SI200432296T SI2218737T1 (sl) 2003-12-24 2004-12-23 Humanizirana anti-NGF protitelesa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200432296T SI2218737T1 (sl) 2003-12-24 2004-12-23 Humanizirana anti-NGF protitelesa

Country Status (19)

Country Link
US (7) US8296079B2 (enExample)
EP (4) EP2138512B8 (enExample)
JP (4) JP4652341B2 (enExample)
CN (2) CN1906212B (enExample)
AT (1) ATE534665T1 (enExample)
AU (4) AU2004303633B2 (enExample)
BR (1) BRPI0418202A (enExample)
CA (2) CA2551796C (enExample)
CY (2) CY1112611T1 (enExample)
DK (3) DK2218737T3 (enExample)
ES (2) ES2377535T3 (enExample)
HU (1) HUE027475T2 (enExample)
IL (2) IL176495A (enExample)
IT (1) ITRM20030601A1 (enExample)
PL (2) PL2138512T3 (enExample)
PT (2) PT2218737E (enExample)
SI (2) SI2138512T1 (enExample)
WO (1) WO2005061540A2 (enExample)
ZA (1) ZA200605200B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
US8394926B2 (en) * 2005-12-21 2013-03-12 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
RS53661B1 (sr) 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
EP2245156A4 (en) * 2008-01-11 2011-02-02 Gene Techno Science Co Ltd HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF
PT2252633E (pt) * 2008-02-04 2013-11-19 Lay Line Genomics Spa Anticorpos anti-trka e seus derivados
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
NZ593937A (en) * 2008-12-08 2014-05-30 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
AU2010216152B2 (en) * 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
US8435523B2 (en) * 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
UY32948A (es) * 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2808577C (en) 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
KR20170070272A (ko) * 2011-05-06 2017-06-21 넥스베트 오스트레일리아 피티와이 리미티드 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
LT3498732T (lt) * 2011-05-06 2022-01-10 Zoetis Services Llc Anti-nervų augimo faktorių antikūnai ir jų paruošimo ir naudojimo būdai
GB2528811A (en) * 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2528401A (en) * 2011-05-06 2016-01-20 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2505352B (en) * 2011-05-06 2016-01-27 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
PT2743348T (pt) 2011-08-11 2018-02-23 Astellas Pharma Inc Novo anticorpo anti-ngf humano
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP2859019B1 (en) * 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Humanized anti-trka antibodies with amino acid substitutions
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
CA2936102A1 (en) * 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
ES2874533T3 (es) 2014-02-05 2021-11-05 VM Oncology LLC Composiciones de compuestos y usos de los mismos
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
RU2017129757A (ru) 2015-01-23 2019-02-25 ДжиВиКей БИОСАЕНСЕЗ ПРАЙВИТ ЛИМИТЕД ИНГИБИТОРЫ TrkA КИНАЗЫ
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
BR112017025029A2 (pt) * 2015-05-22 2018-08-07 Astellas Pharma Inc. ?novo fragmento fab de anticorpo ngf anti- humano?.
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
WO2019164970A1 (en) * 2018-02-20 2019-08-29 Emory University Hpv proteins, antibodies, and uses in managing abnormal epithelial cell growth
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
WO2020068557A1 (en) * 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
KR102265434B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
WO2021047599A1 (en) * 2019-09-13 2021-03-18 Beijing Xuanyi Pharmasciences Co., Ltd. Humanized anti-claudin 18.2 (cldn18.2) antibodies
CN113527482B (zh) * 2020-04-17 2023-07-21 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN116178541B (zh) * 2020-08-06 2025-09-30 熙源安健医药(北京)有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
CN114516917B (zh) * 2020-11-20 2022-11-18 广东东阳光药业有限公司 人源化抗TrkA的抗体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
AU656720B2 (en) 1989-12-01 1995-02-16 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
WO1992008483A1 (en) 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
AU9164991A (en) 1990-11-30 1992-06-25 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
AR248044A1 (es) 1992-02-06 1995-05-31 Schering Corp Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
EP0578515A3 (en) * 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5747060A (en) 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DK1255824T3 (da) 1999-08-06 2010-07-19 S I S S A Scuola Internaz Supe Transgene mus til undersøgelse af neurodegenerative syndromer
US6881719B2 (en) * 2000-01-18 2005-04-19 Mcgill University β-turn peptidomimetic cyclic compounds
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
CA2402596A1 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
EP1575477B1 (en) 2001-05-25 2012-04-25 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
CN1684708A (zh) * 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20060147450A1 (en) 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US20040131515A1 (en) * 2003-01-03 2004-07-08 Alexanian Ara J. Material heat treatment system and method statement regarding federally sponsored research or development
WO2004065560A2 (en) 2003-01-18 2004-08-05 Rinat Neuroscience Corp. Methods of screening for modulators of nerve growth factor
PL379983A1 (pl) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
EA013614B1 (ru) * 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
EP1682170A2 (en) 2003-11-07 2006-07-26 Lay Line Genomics SpA Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7522822B2 (en) 2004-01-06 2009-04-21 Robert Trujillo Halogen lamp assembly with integrated heat sink
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
NZ556157A (en) 2005-01-24 2009-09-25 Elan Pharma Int Ltd Specific binding members for NGF
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
US7290968B1 (en) 2006-03-06 2007-11-06 Shih-Chang Wu Extension fixture for turning tool
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
WO2008145142A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
RS53661B1 (sr) * 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
BRPI0822049B1 (pt) 2007-12-17 2021-11-16 Pfizer Limited Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
EP2141593A1 (en) 2008-07-02 2010-01-06 Telefonaktiebolaget L M Ericsson (Publ) Requirement dependent allocation of hardware units to applications
MX2012008982A (es) 2010-02-03 2012-08-23 Morinaga Milk Industry Co Ltd Metodo para fabricar polvo de aloe.
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions

Also Published As

Publication number Publication date
PL2138512T3 (pl) 2012-09-28
CA2688944C (en) 2015-04-07
IL176495A0 (en) 2006-10-05
HUE027475T2 (en) 2016-09-28
US20140316113A1 (en) 2014-10-23
JP4652341B2 (ja) 2011-03-16
US8257710B2 (en) 2012-09-04
AU2009245889A1 (en) 2010-01-07
ZA200605200B (en) 2009-08-26
PT2138512E (pt) 2012-03-05
AU2009245889B2 (en) 2012-12-13
ES2377535T3 (es) 2012-03-28
CN1906212B (zh) 2013-07-17
DK2138512T3 (da) 2012-02-27
AU2012261567A1 (en) 2013-01-10
US20110191872A1 (en) 2011-08-04
JP2009291211A (ja) 2009-12-17
JP2015110601A (ja) 2015-06-18
HK1147268A1 (en) 2011-08-05
EP2218737A3 (en) 2011-05-11
AU2016269485A1 (en) 2017-01-05
DK1709076T3 (da) 2012-08-27
AU2004303633B2 (en) 2011-12-08
US20110105727A1 (en) 2011-05-05
CA2688944A1 (en) 2005-07-07
CY1117303T1 (el) 2017-04-26
US8296079B2 (en) 2012-10-23
US20150218264A1 (en) 2015-08-06
CY1112611T1 (el) 2016-02-10
EP2218737B1 (en) 2015-12-02
BRPI0418202A (pt) 2007-04-17
AU2012261567B2 (en) 2016-09-08
HK1139697A1 (en) 2010-09-24
EP2218737A2 (en) 2010-08-18
SI2218737T1 (sl) 2016-03-31
EP1709076B1 (en) 2012-05-23
EP2308894A3 (en) 2011-05-11
US20110104164A1 (en) 2011-05-05
JP2008500274A (ja) 2008-01-10
EP2308894A2 (en) 2011-04-13
EP2138512B1 (en) 2011-11-23
JP2012126726A (ja) 2012-07-05
IL220128A0 (en) 2012-07-31
CN1906212A (zh) 2007-01-31
ITRM20030601A1 (it) 2005-06-25
EP2138512A1 (en) 2009-12-30
IL176495A (en) 2014-05-28
ES2559429T3 (es) 2016-02-12
US20090300780A1 (en) 2009-12-03
US20110105728A1 (en) 2011-05-05
CN101724070B (zh) 2015-07-08
WO2005061540A2 (en) 2005-07-07
EP2138512B8 (en) 2012-03-14
CA2551796C (en) 2015-11-03
PL2218737T3 (pl) 2016-09-30
DK2218737T3 (en) 2016-02-29
PT2218737E (pt) 2016-03-18
US8877491B2 (en) 2014-11-04
AU2004303633A1 (en) 2005-07-07
EP1709076A2 (en) 2006-10-11
CA2551796A1 (en) 2005-07-07
CN101724070A (zh) 2010-06-09
ATE534665T1 (de) 2011-12-15
US8246956B2 (en) 2012-08-21
WO2005061540A3 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
PT2218737E (pt) Anticorpos anti-ngf humanizados
IN2009KN02655A (enExample)
TR200200735T2 (tr) CTLA-4 için insan monoklonal antikorları
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
DK1461428T3 (da) Fremgangsmåde til at fremstille hybridantistoffer
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
WO2003087131A3 (en) Anti-her2 antibody variants
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2003068801A3 (en) Antibody variants with faster antigen association rates
ATE452147T1 (de) Antikörper mit korrigierten cdr
WO2006039258A3 (en) Human antibodies against parathyroid hormone
EP1491555A4 (en) THE GENE FOR THE LIGHT / HEAVY CHAIN OF THE VARIABLE REGION OF THE MONOCLONAL ANTI-HUMAN HEPATOMAN TONOR HAB18
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
WO2005047325A3 (en) Monkey immunoglobulin sequences